NLA Resources
ApoC3 inhibitors
9 Resources
Knowledge Center
The National Lipid Association is your destination for the science of lipid medicine. Now, everything we know is in one place.
ApoC3 inhibitors
8 Available Resources
Ionis Receives FDA Approval for TRYNGOLZA (Olezarsen) for Adults with FCS
On December 19, 2024, Ionis Pharmaceuticals, Inc. received FDA approval for TRYNGOLZA (Olezarsen) as an adjunct to diet to reduce triglycerides…
S7E10: Fresh from Munich: Plozasiran and the SHASTA-3 & SHASTA-4 Trial Results
Hot off the European Society of Cardiology Congress in Munich, this Lipid Insights episode takes a closer look at a…
Industry Innovations | Episode 7: A New Era for FCS: Diagnosis, Daily Life & the Science That’s Changing Everything
Familial chylomicronemia syndrome (FCS) is one of the rarest and most challenging lipid disorders to manage, but the landscape is…
Industry Innovations | Episode 2: From Innovation to Impact: The RNA Interference Era Begins
Dr. Bruce Given shares insights into Arrowhead Pharmaceuticals’ innovative approach to siRNA therapeutics and the company’s growing role in lipid…
BALANCE: New Triglyceride-Lowering Drugs
Practical Pearls – TG-Targets ApoC3 & ANGPTL3
Practical Pearls – PALISADE Trial and Plozasiran, a new triglyceride-lowering drug
S5E2: Palisade Phase 3 Data
Alan Brown, MD, FACC, MNLA talks with Robert A. Hegele MD, FRCP about the Palisade Phase 3 Data.
Recognition and Management of Persistent Chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology
Patients with persistent chylomicronemia and alarm features have a very high risk of acute pancreatitis, similar to FCS.
Join the NLA
Become A Member
When you become a member of the NLA, you become part of a collegial multidisciplinary group of leaders dedicated to improving lipid and cardiometabolic health.
